Tissue-Based Biomarkers Important for Prognostication and Management of Genitourinary Tumors, Including Surrogate Markers of Genomic Alterations - 30/01/25

Doi : 10.1016/j.path.2024.10.002

Leonie Beauchamp, MD ^a,^{^{1
Present address: Toronto General Hospital, Room 11E220, 200 Elizabeth Street, Toronto, Ontario, M5G 2C4}}, Shreeya Indulkar, MD ^a,^{^{2
Present address: 1301 D Block, Magnus Sattva, Shaikpet, Hyderabad, Telangana 500008, India.}}, Eric Erak, MD ^a,^{^{3
Present address: 55 Fruit Street, Boston, MA 02114.}}, Mohammad Salimian, MD ^a,^{^{4
Present address: Johns Hopkins Hospital, Weinberg 2243, 401 N. Broadway, Baltimore, MD 21231.}}, Andres Matoso, MD ^a,^b,^c,^⁎
^a Departments of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
^b Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
^c Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA

^∗Corresponding author. The Johns Hopkins Hospital, The Weinberg Building, Room 2243, 401 North Broadway Street, Baltimore, MD 21231.The Johns Hopkins HospitalThe Weinberg BuildingRoom 2243401 North Broadway StreetBaltimoreMD21231

Abstract

A better understanding of the molecular alterations that underlie urologic malignancies and advances in targeted therapies has impacted classification, prognostication, and treatment. In bladder tumors, these advances include the development of antibody-drug conjugates targeting nectin-4 and Trop-2, as well as human epidermal growth factor receptor 2 and immunotherapy. In prostate cancer, assessment of the percentage of Gleason pattern 4, presence of cribriform glands, and molecular alterations, including PTEN and mismatch repair protein loss, have become standard for clinical care. In renal malignancies, alterations in TSC1/2, mammalian target of rapamycin, anaplastic lymphoma kinase, and other genes impact classification and therapeutic decisions.

Le texte complet de cet article est disponible en PDF.

Keywords : Bladder cancer, Prostate cancer, Testicular cancer, Kidney cancer, Biomarker

Plan

Export

Vol 18 - N° 1

P. 175-189 - mars 2025 Retour au numéro

Article précédent

Renal Neoplasia : Rare Subtypes and Uncommon Clinical Presentations
Sounak Gupta, John C. Cheville

| Article suivant

Pediatric Genitourinary Tumors : The Developmental Angle
Claudia M. Salgado, Catherine K. Gestrich, Miguel Reyes-Múgica

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Tissue-Based Biomarkers Important for Prognostication and Management of Genitourinary Tumors, Including Surrogate Markers of Genomic Alterations - 30/01/25

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL